Marta Araujo Castro
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
Year:
2026
Medical treatment of hypercortisolism may be necessary for a high proportion of patients with Cushing syndrome (CS), including those who are not candidates for curative surgery. It may also be used in the presurgical period when hypercortisolism is severe, as long-term treatment following surgical failure or recurrence after surgery, or while waiting for the effects of pituitary radiation in Cushing disease. Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In addition, there are other medical treatments in development that target pituitary signaling pathways, ACTH or its adrenal receptor, or the conversion of cortisol from cortisone by 11ßHSD1. Steroidogenesis inhibitors can be administered using either a titration or a block-and-replace approach. Titration requires adjusting the daily drug dose with the aim of normalizing circulating cortisol levels, whereas the block-and-replace strategy uses higher drug doses to fully suppress endogenous cortisol production, followed by glucocorticoid supplementation. In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS, and mild autonomous cortisol secretion.
Year:
2026
Year:
2026
Year:
2026
Pituitary apoplexy (PA) is a rare but potentially life-threatening endocrine emergency caused by sudden hemorrhage or infarction usually within a pituitary tumor. Clinical presentation is highly variable, ranging from isolated headache to severe visual loss or altered consciousness. Prompt recognition, multidisciplinary evaluation, and timely management are essential to improve outcomes. Recent prospective and real-world studies have challenged the traditional view that urgent surgery is always required. Conservative management has been proposed to be a safe and effective option, although comparisons with the outcomes after surgical intervention are limited by differences in the severity of the clinical picture at presentation of the PA. Clinical decisions remain complex and must consider tumor size, symptom progression, radiological features, and individual comorbidities. The Pituitary Apoplexy Score (PAS) helps guide management but has limitations, as it does not capture key variables such as persistent headache or evolving visual symptoms. Immediate management focuses on hemodynamic stabilization, stress-dose glucocorticoid administration, and neuro-ophthalmological monitoring. Surgical decompression should be considered in patients with progressive visual deterioration or altered consciousness. Follow-up must include hormonal reassessment, ophthalmological evaluation, and imaging surveillance. Although rare, recurrence of PA and tumor regrowth may occur, requiring long-term monitoring. This review provides an updated and pragmatic approach for the diagnosis, acute care, and long-term follow-up of PA, summarizing current evidence and highlighting ongoing controversies, including surgical timing and predictors of conservative treatment failure.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (20)
Betina Biagetti
-
Jung Hee Kim
Seoul National University Hospital
John Newell-Price
Professor of Endocrinology
University of Sheffield
Cristina Lamas Oliveira
F.E.A
University of Castilla-La Mancha
NIKI KARAVITAKI
University of Birmingham
Mónica Marazuela
Universidad Autónoma de Madrid
Mirko Parasiliti-Caprino
MD PhD
University of Turin
Maria de la Iglesia Vaya
Head of Lab
Fisabio
Fabio Bioletto
University of Turin
Holger Schneider
LMU University Hospital
Silvia Monticone
Research Scientist
University of Turin
Georgios Tsermoulas
University of Birmingham
Manel Puig-Domingo
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Víctor Rodríguez-Laval
AUT University
Adina F Turcu
University of Michigan
Silvana Sarria Estrada
Hospital Universitari Vall d'Hebron
Piotr Kmieć
assistant professor
Medical University of Gdansk
Gemma C. Monte-Rubio
Head of Bioimaging
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Rebeca Martínez-Hernández
Universidad Autónoma de Madrid
Julie Refardt
Researcher
University Hospital Basel
Make your next move.
Prepare your application
Review drafts before you send them.